Prolight announces last day of trading in BTU and first day of trading in warrants of series TO6 and TO7
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Correction: Incorrectly applied MAR-label in previous press release. Prolight’s Board of Directors have decided to carry out a directed issue of units to underwriters in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Incorrectly […]
Prolight’s Board of Directors have decided to carry out a directed issue of units to underwriters in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight announces outcome in the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight’s board and management increase their shareholdings
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Members […]
Prolight Diagnostics achieves ISO 13485 accreditation
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, today announces that their subsidiary Psyros Diagnostics has gained accreditation to the industry standard ISO 13485, which sets out the requirements for a quality management system (QMS) specific to the medical devices industry. “The accreditation shows that our quality processes meet global quality requirements which is […]
Prolight Diagnostics shows proof of performance in whole blood
Prolight Diagnostics, developer of the digital point-of-care platform Psyros™, has demonstrated that its single molecule detection system gives equivalent performance in whole blood compared to plasma, without having to separate the cells from the sample. “This is a very important breakthrough for our single molecule counting technology. We are not aware of any other single […]
Prolight Diagnostics publishes investor letter for October 2023
Prolight Diagnostics publishes an investor letter for October 2023. In the investor letter, an interview is given with Karl Bullen, COO at Prolight Diagnostics. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: info@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, a first summary of the Congress Annual Scientific Meeting + Clinical Lab Expo in Anaheim, USA is given. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics AB (publ)E-mail: ub@prolightdx.comTelephone: +46 73 582 39 87Website: www.prolightdx.com/en/ About UsProlight Diagnostics, together with […]
Prolight Diagnostics publishes investor letter for July 2023
Prolight Diagnostics publishes an investor letter for July 2023. In the investor letter, you can read about the launch of the company’s new website and that Prolight Diagnostics is now present at the 2023 AACC Annual Scientific Meeting + Clinical Lab Expo in the USA. Link to investor letters:https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Prolight Diagnostics […]
